1-3 of 3
Jorie Versmissen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage

In Collection
Cardiovascular-Oncology
Katrina M. Mirabito Colafella, Daan C.H. van Dorst, Rugina I. Neuman, Leni van Doorn, Karla Bianca Neves, Augusto C. Montezano, Ingrid M. Garrelds, Richard van Veghel, René de Vries, Estrellita Uijl, Marian C. Clahsen-van Groningen, Hans J. Baelde, Anton H. van den Meiracker, Rhian M. Touyz, Willy Visser, A.H. Jan Danser, Jorie Versmissen
Journal: Clinical Science
Clin Sci (Lond) (2022) 136 (9): 675–694.
DOI: https://doi.org/10.1042/CS20220182
Published: 10 May 2022
View article titled, Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
Click here to open pdf in another window PDF for Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
Includes: Supplementary data
Articles

Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?

In Collection
Cardiovascular-Oncology
Daan C.H. van Dorst, Leni van Doorn, Katrina M. Mirabito Colafella, Olivier C. Manintveld, H. Carlijne Hassing, A.H. Jan Danser, Ron H.J. Mathijssen, Jorie Versmissen
Journal: Clinical Science
Clin Sci (Lond) (2021) 135 (14): 1649–1668.
DOI: https://doi.org/10.1042/CS20200300
Published: 20 July 2021
View article titled, Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
Click here to open pdf in another window PDF for Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
Articles

Endothelin receptor antagonism during preeclampsia: a matter of timing?

Emilie Hitzerd, Rugina I. Neuman, Katrina M. Mirabito Colafella, Irwin K.M. Reiss, Anton H. van den Meiracker, A.H. Jan Danser, Willy Visser, Jorie Versmissen, Langeza Saleh
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (12): 1341–1352.
DOI: https://doi.org/10.1042/CS20190464
Published: 20 June 2019
View article titled, Endothelin receptor antagonism during preeclampsia: a matter of timing?
Click here to open pdf in another window PDF for Endothelin receptor antagonism during preeclampsia: a matter of timing?
Includes: Supplementary data